210 related articles for article (PubMed ID: 30788003)
1. Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells.
Huang B; Wang J; Chen Q; Qu C; Zhang J; Chen E; Zhang Y; Wang Y; Ni L; Liang T
Am J Transl Res; 2019; 11(1):473-485. PubMed ID: 30788003
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy.
Xiong J; Wang D; Wei A; Ke N; Wang Y; Tang J; He S; Hu W; Liu X
Oncotarget; 2017 Dec; 8(64):107500-107512. PubMed ID: 29296182
[TBL] [Abstract][Full Text] [Related]
3. Development of Gemcitabine-Modified miRNA Mimics as Cancer Therapeutics for Pancreatic Ductal Adenocarcinoma.
Yuen JG; Hwang GR; Fesler A; Intriago E; Pal A; Ojha A; Ju J
bioRxiv; 2023 Aug; ():. PubMed ID: 37645827
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma.
Zhou L; Jia S; Ding G; Zhang M; Yu W; Wu Z; Cao L
J Cancer; 2019; 10(21):5031-5040. PubMed ID: 31602254
[TBL] [Abstract][Full Text] [Related]
5. OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma.
Ding J; Li H; Liu Y; Xie Y; Yu J; Sun H; Xiao D; Zhou Y; Bao L; Wang H; Gao C
Front Oncol; 2021; 11():698302. PubMed ID: 34804914
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugs.
Zhao B; Qin C; Li Z; Wang Y; Li T; Cao H; Yang X; Li T; Wang W
Cancer Cell Int; 2022 Dec; 22(1):374. PubMed ID: 36457017
[TBL] [Abstract][Full Text] [Related]
7. A tumor microenvironment-stimuli responsive nano-prodrug for overcoming gemcitabine chemoresistance by co-delivered miRNA-21 modulator.
Zhang F; Yao Z; Jin P; Xu M; Hu Q; Chen Y; Que R; Liang T
Biomed Mater; 2023 Apr; 18(3):. PubMed ID: 36990101
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-663a is downregulated in non-small cell lung cancer and inhibits proliferation and invasion by targeting JunD.
Zhang Y; Xu X; Zhang M; Wang X; Bai X; Li H; Kan L; Zhou Y; Niu H; He P
BMC Cancer; 2016 May; 16():315. PubMed ID: 27184257
[TBL] [Abstract][Full Text] [Related]
9. Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma.
Okuno K; Xu C; Pascual-Sabater S; Tokunaga M; Han H; Fillat C; Kinugasa Y; Goel A
Pharmaceuticals (Basel); 2022 Sep; 15(10):. PubMed ID: 36297310
[TBL] [Abstract][Full Text] [Related]
10. Functional Significance and Therapeutic Potential of miR-15a Mimic in Pancreatic Ductal Adenocarcinoma.
Guo S; Fesler A; Huang W; Wang Y; Yang J; Wang X; Zheng Y; Hwang GR; Wang H; Ju J
Mol Ther Nucleic Acids; 2020 Mar; 19():228-239. PubMed ID: 31846800
[TBL] [Abstract][Full Text] [Related]
11. Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma.
Okuno K; Xu C; Pascual-Sabater S; Tokunaga M; Takayama T; Han H; Fillat C; Kinugasa Y; Goel A
Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672630
[TBL] [Abstract][Full Text] [Related]
12. N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2.
Yao M; Hong Y; Liu Y; Chen W; Wang W
Exp Ther Med; 2017 Sep; 14(3):2101-2107. PubMed ID: 28962130
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer.
Gu Z; Du Y; Zhao X; Wang C
Cancer Lett; 2021 Aug; 521():98-108. PubMed ID: 34461181
[TBL] [Abstract][Full Text] [Related]
14. Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma.
Sun H; Ge Y; Liu J; Li Z; Li H; Zhao T; Wang X; Feng Y; Wang H; Gao S; Shi L; Yang S; Sun P; Chang A; Hao J; Huang C
Oncogene; 2024 Mar; 43(11):776-788. PubMed ID: 38243080
[TBL] [Abstract][Full Text] [Related]
15. Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer.
Ebrahimi S; Hosseini M; Ghasemi F; Shahidsales S; Maftouh M; Akbarzade H; Parizadeh SA; Hassanian SM; Avan A
Curr Pharm Des; 2016; 22(42):6444-6450. PubMed ID: 27539232
[TBL] [Abstract][Full Text] [Related]
16. miR-663a inhibits tumor growth and invasion by regulating TGF-β1 in hepatocellular carcinoma.
Zhang C; Chen B; Jiao A; Li F; Sun N; Zhang G; Zhang J
BMC Cancer; 2018 Nov; 18(1):1179. PubMed ID: 30486878
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma.
Zhao C; Zhang J; Zhang S; Yu D; Chen Y; Liu Q; Shi M; Ni C; Zhu M
Oncol Rep; 2013 Jul; 30(1):276-84. PubMed ID: 23612862
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.
Xue Y; Abou Tayoun AN; Abo KM; Pipas JM; Gordon SR; Gardner TB; Barth RJ; Suriawinata AA; Tsongalis GJ
Cancer Genet; 2013 Jun; 206(6):217-21. PubMed ID: 23933230
[TBL] [Abstract][Full Text] [Related]
19. microRNA-218 promotes gemcitabine sensitivity in human pancreatic cancer cells by regulating HMGB1 expression.
Liu Z; Du R; Long J; Guo K; Ge C; Bi S; Xu Y
Chin J Cancer Res; 2015 Jun; 27(3):267-78. PubMed ID: 26157323
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
